Immunology & rheumatology generics
Biologics and JAK inhibitors for rheumatoid arthritis, psoriasis, ankylosing spondylitis, IBD and multiple sclerosis.
5 molecules. Open any card for the full monograph and price table.
Teriflunomide
Originator: Aubagio · Genzyme Corporation, a Sanofi company (US label lists Genzyme Corporation, Cambridge, MA; Sanofi markets Aubagio)
FDA: treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated synd
Immunology & rheumatology →
Adalimumab High demand
Originator: Humira · AbbVie (originally developed and marketed by Abbott Laboratories; initial U.S. approval 2002)
Rheumatoid arthritis: moderately to severely active RA in adults — reduces signs/symptoms, induc
Immunology & rheumatology →
Tofacitinib High demand
Originator: Xeljanz / Xeljanz XR · Pfizer (initial U.S. approval 2012)
Rheumatoid arthritis: moderately to severely active RA in adults who have had an inadequate resp
from BDT 30 (US$0.24 / 5 mg) · 15manufacturers
Immunology & rheumatology →
Baricitinib
Originator: Olumiant · Eli Lilly and Company (co-developed with Incyte; initial U.S. approval 2018)
Rheumatoid arthritis: moderately to severely active RA in adults who have had an inadequate resp
from BDT 20 (US$0.16 / 2 mg) · 10manufacturers
Immunology & rheumatology →
Infliximab
Originator: Remicade · Janssen Biotech / Johnson & Johnson (originally Centocor); initial U.S. approval 1998
Crohn's disease: reducing signs and symptoms and inducing and maintaining clinical remission in
Immunology & rheumatology →
Therapeutic areas
Medical and legal notice
This page is an information resource for healthcare professionals, licensed importers and patients under medical care. It is not medical advice, not a prescription service, and not an offer to sell prescription medicines to the public.
Need a verified quotation?
Send us the molecule, strength, pack size, quantity and destination country. We reply with a batch-traceable quotation, certificates of analysis and shipping documentation.
We supply licensed pharmacies, hospitals, importers and distributors — not direct-to-consumer patients.